Vestal Point Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Vestal Point Capital's MLTX Position: Q3 2026 in Review
Vestal Point Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 525,000 shares worth $6.14M. The stake represents 0.16% of the portfolio and ranks #48 among its holdings. This is a return to the name: Vestal Point Capital previously reported a position in MLTX as recently as Q2 2025.
Vestal Point Capital first reported a position in MLTX in Q1 2025 and has held it in 3 quarters since. The position peaked at $26M in Q2 2025. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Vestal Point Capital held 525,000 shares of MoonLake Immunotherapeutics worth $6.14M as of Q3 2026.
- MoonLake Immunotherapeutics was a new Vestal Point Capital position in Q3 2026.
- MoonLake Immunotherapeutics made up 0.16% of Vestal Point Capital's portfolio in Q3 2026, its #48 holding.
- Vestal Point Capital first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 3 quarters since.
- Vestal Point Capital's MoonLake Immunotherapeutics position peaked at $26M in Q2 2025.
- 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Vestal Point Capital's 13F filing for Q3 2026, filed 16 Nov 2026.